WO2011081415A3 - c-Met의 발현을 저해하는 siRNA 및 이를 포함하는 항암 조성물 - Google Patents

c-Met의 발현을 저해하는 siRNA 및 이를 포함하는 항암 조성물 Download PDF

Info

Publication number
WO2011081415A3
WO2011081415A3 PCT/KR2010/009440 KR2010009440W WO2011081415A3 WO 2011081415 A3 WO2011081415 A3 WO 2011081415A3 KR 2010009440 W KR2010009440 W KR 2010009440W WO 2011081415 A3 WO2011081415 A3 WO 2011081415A3
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
met
met expression
inhibiting
same
Prior art date
Application number
PCT/KR2010/009440
Other languages
English (en)
French (fr)
Other versions
WO2011081415A2 (ko
Inventor
김선옥
김상희
조은아
인창훈
Original Assignee
주식회사 삼양사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/519,936 priority Critical patent/US20130023578A1/en
Application filed by 주식회사 삼양사 filed Critical 주식회사 삼양사
Priority to CA2785983A priority patent/CA2785983A1/en
Priority to JP2012547018A priority patent/JP2013515498A/ja
Priority to EP10841247.9A priority patent/EP2520651A4/en
Priority to AU2010339082A priority patent/AU2010339082A1/en
Priority to CN2010800650207A priority patent/CN102782133A/zh
Publication of WO2011081415A2 publication Critical patent/WO2011081415A2/ko
Publication of WO2011081415A3 publication Critical patent/WO2011081415A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

c-Met 전사체 (mRNA transcript) 염기서열에 상보적으로 결합하여 세포 내에서 c-Met의 발현을 억제함과 동시에 면역반응을 유발하지 않는(optionally) 작은 간섭 리보핵산 (small interfering RNA, siRNA) 및 상기 siRNA의 암의 예방 및/또는 치료에 있어서의 용도가 제공된다. 상기 c-Met을 암호화하는 mRNA와 상보 결합할 수 있는 siRNA는 리보핵산 매개 간섭현상 (RNA interference, RNAi)에 의해 거의 모든 암세포에 공통적으로 과발현되는 c-Met의 발현을 억제하여 암세포의 증식 및 전이를 저해 할 수 있으므로, 항암제로서 유용하게 이용될 수 있다.
PCT/KR2010/009440 2009-12-31 2010-12-28 c-Met의 발현을 저해하는 siRNA 및 이를 포함하는 항암 조성물 WO2011081415A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/519,936 US20130023578A1 (en) 2009-12-31 2009-12-28 siRNA for inhibition of c-Met expression and anticancer composition containing the same
CA2785983A CA2785983A1 (en) 2009-12-31 2010-12-28 Sirna for inhibition of c-met expression and anticancer composition containing the same
JP2012547018A JP2013515498A (ja) 2009-12-31 2010-12-28 ｃ−Ｍｅｔの発現を阻害するｓｉＲＮＡ及びこれを含む抗癌組成物
EP10841247.9A EP2520651A4 (en) 2009-12-31 2010-12-28 SIRNA FOR INHIBITING THE C-MET EXPRESSION AND ANTICREPLAY COMPOSITION THEREWITH
AU2010339082A AU2010339082A1 (en) 2009-12-31 2010-12-28 siRNA for inhibiting c-Met expression and an anti-cancer composition comprising the same
CN2010800650207A CN102782133A (zh) 2009-12-31 2010-12-28 抑制c-Met表达的siRNA及含有所述siRNA的抗癌组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090135665 2009-12-31
KR10-2009-0135665 2009-12-31

Publications (2)

Publication Number Publication Date
WO2011081415A2 WO2011081415A2 (ko) 2011-07-07
WO2011081415A3 true WO2011081415A3 (ko) 2011-12-01

Family

ID=44227018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/009440 WO2011081415A2 (ko) 2009-12-31 2010-12-28 c-Met의 발현을 저해하는 siRNA 및 이를 포함하는 항암 조성물

Country Status (8)

Country Link
US (1) US20130023578A1 (ko)
EP (1) EP2520651A4 (ko)
JP (1) JP2013515498A (ko)
KR (1) KR101252799B1 (ko)
CN (1) CN102782133A (ko)
AU (1) AU2010339082A1 (ko)
CA (1) CA2785983A1 (ko)
WO (1) WO2011081415A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
SG10201803802YA (en) 2013-11-05 2018-06-28 3M Innovative Properties Co Sesame oil based injection formulations
KR102291465B1 (ko) * 2014-01-24 2021-08-18 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
KR101913693B1 (ko) * 2016-12-14 2018-10-31 사회복지법인 삼성생명공익재단 SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
US10590416B2 (en) * 2017-07-06 2020-03-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
AU2019300911B2 (en) * 2018-07-10 2023-06-01 Genemedicine Co., Ltd. Anti-tumor composition
CN111849992A (zh) * 2020-08-17 2020-10-30 南通大学 靶向c-Met基因的siRNA分子及其应用
JP2023554111A (ja) * 2020-12-16 2023-12-26 インダストリー－アカデミック コーオペレイション ファウンデーション キョンサン ナショナル ユニバーシティ 遺伝子発現および抑制が同時に可能な核酸構造体
KR20220128307A (ko) * 2021-03-12 2022-09-20 (주)큐리진 c-MET 유전자 및 PD-L1 유전자의 발현을 동시에 억제하는 핵산
CN114480400B (zh) * 2022-03-17 2023-04-21 郑州大学第一附属医院 一种与大肠癌相关的核苷酸分子及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
PT1581812E (pt) * 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon
US7872117B2 (en) * 2004-03-26 2011-01-18 Van Andel Research Institute c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity
EP1951263A4 (en) * 2005-11-21 2009-11-18 Johnson & Johnson Res Pty Ltd MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
KR100949791B1 (ko) 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
WO2009143281A2 (en) * 2008-05-20 2009-11-26 Intradigm Corporation Compositions comprising c-met sirna and methods of use thereof
WO2011130065A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COREY.: "Chemical modification: the key to clinical application of RNA interference?", J CLIN INVEST., vol. 117, no. 12, December 2007 (2007-12-01), pages 3615 - 3622, XP002558508, DOI: doi:10.1172/JCI33483 *
HAN ET AL.: "Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells", PROC NATL ACAD SCI U S A., vol. 104, no. 30, 24 July 2007 (2007-07-24), pages 12422 - 12427, XP002608373, DOI: doi:10.1073/pnas.0701635104 *
SIOUD ET AL.: "Molecular basis for the immunostimulatory potency of small interfering RNAs", J BIOMED BIOTECHNOL., vol. 2006, no. 4, 2006, pages 23429 *
SIPA ET AL.: "Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA", RNA., vol. 13, no. 8, August 2007 (2007-08-01), pages 1301 - 1316, XP002595128 *
TAKEUCHI ET AL.: "X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling", CLIN CANCER RES., vol. 11, no. 21, 1 November 2005 (2005-11-01), pages 7621 - 7628, XP002543074, DOI: doi:10.1158/1078-0432.CCR-05-0479 *
VARGHESE ET AL.: "Conformationally constrained 2'-N,4'-C-ethylene-bridged thymidine (aza-ENA-T): synthesis, structure, physical, and biochemical studies ofaza-ENA-T- modified oligonucleotides", J AM CHEM SOC., vol. 128, no. 47, 29 November 2006 (2006-11-29), pages 15173 - 15187, XP003018390, DOI: doi:10.1021/ja0634977 *

Also Published As

Publication number Publication date
US20130023578A1 (en) 2013-01-24
KR20110079529A (ko) 2011-07-07
WO2011081415A2 (ko) 2011-07-07
KR101252799B1 (ko) 2013-04-09
AU2010339082A1 (en) 2012-08-02
EP2520651A2 (en) 2012-11-07
CA2785983A1 (en) 2011-07-07
EP2520651A4 (en) 2013-07-31
CN102782133A (zh) 2012-11-14
JP2013515498A (ja) 2013-05-09

Similar Documents

Publication Publication Date Title
WO2011081415A3 (ko) c-Met의 발현을 저해하는 siRNA 및 이를 포함하는 항암 조성물
WO2011008730A3 (en) Chemical modification of small hairpin rnas for inhibition of gene expression
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
WO2010041913A3 (ko) Grs 단백질 또는 이의 단편의 신규한 용도
WO2011139911A3 (en) Lipid formulated single stranded rna
MX2018013398A (es) Composiciones y metodos para inhibir la expresion de transtiretina.
EP2591770A3 (en) Compositions for siRNA delivery and methods of manufacturing and using same
WO2012091496A3 (en) siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
EP3693464A3 (en) Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2010045384A3 (en) Short hairpin rnas for inhibition of gene expression
WO2009131887A3 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
WO2008151631A8 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
WO2009058907A3 (en) Targeting micrornas for the treatment of liver cancer
WO2012006241A3 (en) Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
WO2008094516A8 (en) Multi-targeting short interfering rnas
WO2012006243A3 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
WO2011116152A3 (en) Delivery of agents using interfering nanoparticles
WO2012027713A3 (en) Compositions and methods for inhibition of snca
WO2013034989A3 (en) Microrna-based methods and assays for osteosarcoma
WO2010007522A8 (en) Rna antagonists targeting gli2
WO2010083312A3 (en) Micro-rna biomarker in cancer
CA2810119C (en) Clec14a inhibitors
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080065020.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10841247

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2785983

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012547018

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010339082

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6566/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13519936

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010841247

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010339082

Country of ref document: AU

Date of ref document: 20101228

Kind code of ref document: A